CG Oncology Inc. (NASDAQ: CGON) Stock Information | RedChip

CG Oncology Inc. (NASDAQ: CGON)


$27.8500
-0.8200 ( -2.59% ) 48.9K

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Market Data


Open


$27.8500

Previous close


$28.6700

Volume


48.9K

Market cap


$2.15B

Day range


$27.8350 - $28.9540

52 week range


$25.7700 - $50.2300

SEC Filings


Form Type Description Pages Date
3 Insider transactions 2 Jan 24, 2024
3 Insider transactions 2 Jan 24, 2024
3 Insider transactions 2 Jan 24, 2024
3 Insider transactions 2 Jan 24, 2024
3 Insider transactions 2 Jan 24, 2024
3 Insider transactions 2 Jan 24, 2024

Latest News